<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02597361</url>
  </required_header>
  <id_info>
    <org_study_id>P140918</org_study_id>
    <secondary_id>2015-001065-76</secondary_id>
    <nct_id>NCT02597361</nct_id>
  </id_info>
  <brief_title>Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome (ARCADE)</brief_title>
  <acronym>ARCADE</acronym>
  <official_title>Angiotensin II Receptor Blockade in Vascular Ehlers Danlos Syndrome: a Double Blind, Randomized, Placebo Controlled, Multicenter Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to verify the hypothesis that patients with Vascular Ehlers Danlos syndrome
      (vEDS) should benefit of the blockade of angiotensin (Ang) II noxious effects on their
      vasculature affected by a defect in type III collagen in addition to the effects celiprolol.
      This randomized, double blind, placebo controlled trial compares the administration of the
      Ang II type I receptor blocker (ARB) — irbesartan— to placebo over a 2-year period in vEDS
      patients with the main objective to reduce the incidence of both symptomatic and asymptomatic
      vascular events.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      vEDS is a rare life-threatening inherited condition due to mutations at the COL3A1 gene
      encoding the pro-alpha 1 chain of type III procollagen (OMIM #130050) with unpredictable and
      recurring arterial dissections/aneurysms starting in the early adulthood. The investigators
      have previously shown that a treatment with 200-400 mg per day of celiprolol, reduces both
      fatal and non-fatal vascular events in patients with vEDS. If tolerated, the treatment is now
      the standard treatment for vEDS. However, despite celiprolol , symptomatic and asymptomatic
      arterial events continue to occur in vEDS patients. Recent findings suggest a possible
      deleterious effect of endogenous Angiotensin II on medium size arteries in vEDS patients. The
      hypothesis of this study is that the blockade of endogenous Ang II will provide supplemental
      vascular protection and thus reduce recurrence of arterial events in vEDS patients.

      The primary objective of this study is to determine in patients with molecularly proven vEDS,
      whether an Ang II receptor blocker, prescribed at an optimally tolerated dose combined with
      the reference celiprolol treatment, decreases the 24 months rate of both asymptomatic and
      symptomatic cardiovascular (CV) events when compared to placebo.

      Methodology:

      Multicenter, double-blind, randomized (1:1), placebo-controlled, parallel group, study with
      blind endpoint evaluation in adult vEDS patients.

      Main criteria for inclusion:

      Patients of both sexes aged 18 to 70 years with molecularly proven vEDS, not in an acute
      phase of the disease, with no contra-indication for taking an Ang II blocker.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular morbidity and mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Total number of any non-fatal and fatal cardiovascular events or events related to vEDS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arterial lesions</measure>
    <time_frame>2 years</time_frame>
    <description>number and severity of arterial lesions detected by CTA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of any symptomatic cardiovascular event</measure>
    <time_frame>2 years</time_frame>
    <description>CV death; any morbid and fatal events related to vEDS; Any non fatal CV event; Non-fatal stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of new asymptomatic arterial lesions (aneurysm, dissection), detected by a systematic CTA</measure>
    <time_frame>2 years</time_frame>
    <description>Arterial dissection/rupture/aneurysm in any vascular bed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first symptomatic clinical morbid and fatal events</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unplanned hospitalization for any vEDS related event</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of arterial lesions detected by vascular DUS</measure>
    <time_frame>2 years</time_frame>
    <description>Echo duplex ultrasound made at inclusion, 6, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of arterial lesions worsened during follow-up</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PWV (Pulse Wave Velocity)</measure>
    <time_frame>2 years</time_frame>
    <description>Applanation tonometry made at randomization visit, 6, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in large arteries properties (diameter, wall stress, stiffness)</measure>
    <time_frame>2 years</time_frame>
    <description>Echotracking made at randomization visit, 6, 12, 18 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in office systolic/diastolic BP</measure>
    <time_frame>2 years</time_frame>
    <description>Vital signs (BP and HR) measured by automatic device at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in estimated glomerular filtration rate (MDRD)</measure>
    <time_frame>2 years</time_frame>
    <description>eGFR evaluated at each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability and safety of the irbesartan assessed by orthostatic hypotension, plasma creatinine, plasma K+ evaluated at each visit</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>2 years</time_frame>
    <description>Morisky questionnaire at each visit and spot urine for drug determination (celiprolol and irbesartan urinary detection) made at randomization visit and 3, 12 and 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>SF36 and HADS questionnaires submitted to participants at randomization visit, 6, 12 and 24 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Ehlers-Danlos Syndrome, Vascular Type</condition>
  <arm_group>
    <arm_group_label>Irbesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Irbesartan: 150 or 300 mg o.d. for 2 years.The up-titration of irbesartan from 150 mg to 300 mg o.d. occurs during the first 8 weeks following randomization and will be driven by clinical, hemodynamic and biological (plasma creatinine and K) tolerability.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once or twice per day for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization</description>
    <arm_group_label>Irbesartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo o.d. to match 150mg or 300mg irbesartan tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with genetically-proven vEDS (presence of a pathogenic mutation at the COL3A1
             gene);

          -  Age ≥18 years and &lt;70 years;

          -  Men and women with reliable contraception or negative beta-HCG at screening;

          -  Celiprolol at the optimal tolerated dose since at least 12 weeks;

          -  vEDS patient fully intolerant to celiprolol but not treated with any other drug active
             on the vascular system, except another beta-blocker;

          -  No compelling indication for ARB therapy (renal infarction, hypertension, proteinuric
             nephropathy, chronic heart failure, myocardial infarction, stroke);

          -  Estimated glomerular filtration rate (GFR) ≥ 30ml/min/1,73m2 (MDRD Formula);

          -  Normal or clinically acceptable 12-lead ECG;

          -  Written informed consent to participate in the study.

        Exclusion Criteria:

        General criteria

          -  Unlikely to co-operate in the study and/or poor compliance anticipated by the
             investigator, e.g., uncooperative attitude, inability to return for follow-up visit,
             and unlikelihood of completing the study;

          -  Participation in another interventional therapeutic study at the same time or within 3
             months prior to the beginning of the present study;

          -  Participant not affiliated to the French social security;

          -  No written informed consent;

          -  Severe contrast media allergy, not amenable to pre-treatment Medical and therapeutic
             criteria

          -  History of previous symptomatic visceral complication (any CV event, pulmonary or
             digestive event) in the 3 months preceding the inclusion;

          -  Formal indication for an antihypertensive medication (office BP ≥140/90 mmHg on
             celiprolol on at least two separated visits, confirmed by daytime ambulatory BP or
             home BP ≥ 135/85 mmHg);

          -  Concomitant treatment with renin-angiotensin-aldosterone system blocking agents apart
             from the study drug, e.g. ACEI, ARB or aldosterone-antagonist or any renin inhibitor,
             if given for an elective indication (heart failure, renal infarction, chronic kidney
             disease, proteinuria, myocardial infarction, stroke);

          -  Any cardiac condition that justifies a specific medical care (i.e. second or third
             degree auriculo-ventricular block, potentially life threatening arrhythmia or other
             uncontrolled arrhythmia or persistent arrhythmia, clinically significant valvular
             heart disease);

          -  Known significant renal artery stenosis with evidence of renal ischemia (on Duplex
             ultrasound, CTA, or other exam);

          -  Any concurrent life threatening condition other than vEDS with a life expectancy less
             than 2 years;

          -  Likely allergy or hypersensitivity to irbesartan, based on known allergies to drugs of
             the same class, or which in the opinion of the investigator suggests an increased
             potential for an adverse hypersensitivity as well as known or suspected
             contraindications to the study drug;

          -  Any condition that in the opinion of the investigator would jeopardize the evaluation
             of efficacy or safety;

          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a
             female after conception and until the termination of gestation, confirmed by a
             positive Human Chorionic Gonadotropin (hCG) laboratory test (&gt;5 mIU/ml);

          -  Women of child-bearing potential (WOCBP) without reliable contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier JEUNEMAITRE, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AP-HP, INSERM</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier JEUNEMAITRE, MD,PHD</last_name>
    <phone>+33 1 56 09 38 80</phone>
    <email>xavier.jeunemaitre@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael FRANK, MD</last_name>
    <phone>+33 1 56 09 50 40</phone>
    <email>michael.frank@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU DE BORDEAUX - Hopital Saint Andre</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joel CONSTANS, MD,PHD</last_name>
      <phone>+33 5 56 79 57 16</phone>
      <email>joel.constans@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE LYON - Hopital Femme Mere Enfant</name>
      <address>
        <city>Bron</city>
        <zip>69500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie DUPUIS-GIROD, MD,PHD</last_name>
      <phone>+33 4 27 85 65 24</phone>
      <email>sophie.dupuis-girod@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE CAEN - Hopital Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damien LANEELLE, MD,PHD</last_name>
      <phone>+33 2 31 06 53 27</phone>
      <email>laneelle-d@chu-caen.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE TOURS - Hopital Trousseau</name>
      <address>
        <city>Chambray-les-Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriela GEORGESCOU, MD</last_name>
      <phone>+33 2 47 47 46 25</phone>
      <email>g.georgescou@chu-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE GRENOBLE - Hopital Albert Michallon</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe SEINTURIER, MD,PHD</last_name>
      <phone>+33 4 76 76 89 60</phone>
      <email>cseinturier@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE GRENOBLE - Hopital Couple Enfant</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre-Simon JOUK, MD,PHD</last_name>
      <phone>+33 7 76 76 72 85</phone>
      <email>psjouk@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU DE LILLE - Hopital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc LAMBERT, MD</last_name>
      <phone>+33 3 20 44 42 96</phone>
      <email>marc.lambert@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE LYON - Hopital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques NINET, MD,PHD</last_name>
      <phone>+33 4 72 11 75 71</phone>
      <email>jacques.ninet@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HM - Hopital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence BAL-THEOLEYRE, MD</last_name>
      <phone>+33 4 91 38 81 20</phone>
      <email>laurence.bal@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE MONTPELLIER - Hopital Saint Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle QUERE, MD,PHD</last_name>
      <phone>+33 67 33 70 25</phone>
      <email>i-quere@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE NANTES - Hopital Hotel-Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marc-Antoine PISTORIUS, MD</last_name>
      <phone>+33 2 40 08 33 34</phone>
      <email>marc.pistorius@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP - Hopital Europeen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xavier JEUNEMAITRE, MD,PHD</last_name>
      <phone>+33 1 56 09 38 80</phone>
      <email>xavier.jeunemaitre@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Michael FRANK, MD</last_name>
      <phone>+33 1 56 09 50 40</phone>
      <email>michael.frank@aphp.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU DE TOULOUSE - Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie JULIA, MD</last_name>
      <phone>+33 5 61 77 90 55</phone>
      <email>julia.s@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU DE TOULOUSE - Hopital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra BURA-RIVIERE, MD,PHD</last_name>
      <phone>+33 5 61 32 24 38</phone>
      <email>bura-riviere.a@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU DE NANCY - Institut Lorrain du Coeur et des Vaisseaux</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis WAHL, MD,PHD</last_name>
      <phone>+33 3 83 15 36 14</phone>
      <email>d.wahl@chu.nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Frank M, Albuisson J, Ranque B, Golmard L, Mazzella JM, Bal-Theoleyre L, Fauret AL, Mirault T, Denarié N, Mousseaux E, Boutouyrie P, Fiessinger JN, Emmerich J, Messas E, Jeunemaitre X. The type of variants at the COL3A1 gene associates with the phenotype and severity of vascular Ehlers-Danlos syndrome. Eur J Hum Genet. 2015 Dec;23(12):1657-64. doi: 10.1038/ejhg.2015.32. Epub 2015 Mar 11.</citation>
    <PMID>25758994</PMID>
  </reference>
  <results_reference>
    <citation>Faugeroux J, Nematalla H, Li W, Clement M, Robidel E, Frank M, Curis E, Ait-Oufella H, Caligiuri G, Nicoletti A, Hagege A, Messas E, Bruneval P, Jeunemaitre X, Bergaya S. Angiotensin II promotes thoracic aortic dissections and ruptures in Col3a1 haploinsufficient mice. Hypertension. 2013 Jul;62(1):203-8. doi: 10.1161/HYPERTENSIONAHA.111.00974. Epub 2013 Apr 29.</citation>
    <PMID>23630948</PMID>
  </results_reference>
  <results_reference>
    <citation>Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010 Oct 30;376(9751):1476-84. doi: 10.1016/S0140-6736(10)60960-9. Epub 2010 Sep 7. Erratum in: Lancet. 2016 Aug 6;388(10044):564. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.</citation>
    <PMID>20825986</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 5, 2015</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ehlers-Danlos syndrome, vascular type</keyword>
  <keyword>Type 2 Angiotensin Receptor Blockers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ehlers-Danlos Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
    <mesh_term>Angiotensin II</mesh_term>
    <mesh_term>Angiotensinogen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

